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PYCNOGENOL: A NUTRACEUTICAL FOR VENOUS HEALTH
Om P. Gulati  
Horphag Research Management Ltd., Geneva, Switzerland
Recent studies utilizing highly sophisticated methodology and techniques were able to provide a new insight into the molecular 
mechanism of the biological activity of various botanical extracts. The present review provides an update of the multifaceted 
biological profile of the nutraceutical Pycnogenol® in venous health, using a target oriented approach in light of pathophysiol-
ogy of chronic venous insufficiency. Pycnogenol is French maritime pine bark extract produced by extraction of the outer bark of 
Pinus pinaster Ait. Subsp. atlantica. Pycnogenol has strong antioxidant profile proven by in vitro and in vivo studies in animals 
and further confirmed in clinical trials. Its strong antioxidant profile, vasodilator activity, antithrombotic effect and its collagen 
stabilizing property make it a unique health product. It reduces edema of legs and lowers chances of developing deep venous 
thrombosis and skin ulceration. These properties further qualify Pycnogenol to be a useful food supplement for venous health 
particularly in chronic venous insufficiency. Developing new combination products using synergistic approaches are the future 
trends of research and development to prove efficacy in conditions which involves oxidative stress, inflammation, endothelial 
dysfunction, thrombogenesis, and ulceration. Biomed Rev 2008; 19: 33-43.
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INTRODUCTION
In the recent years, a paradigm shift in the nutritional science 
has been evolved, nutrition research being targeted to molecu-
lar biology, genetics and adipobiology. In essence, the sequenc-
ing of mammalian genomes has initiated the development of 
novel methodologies to study gene expressions for as many 
genes as possible, simultaneously. Additionally, transcriptom-
ics, proteomics, interactomics and metabolomics have opened 
new areas of science, including nutrigenomics (nutritional 
genomics) and pharmacogenomics (1). Hence neutraceuticals 
(food- and botanic-derived products) have been emerging as 
a promising innovative approach for maintaining good health 
and reducing the risk of various diseases. 
  The present review provides an update of the multifaceted 
biological profile of the nutraceutical (botanical) Pycnogenol® 
in venous health, using a target oriented approach in light of 
pathophysiology of chronic venous insufficiency (CVI).
PYCNOGENOL
Pycnogenol is French maritime pine bark extract produced by 
extraction of the outer bark of Pinus pinaster Ait. Subsp. atlan-
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tica. Its specifications are described in the USP 30 - Dietary 
supplements (2). On safety aspects, it is generally recognized 
as safe (GRAS) in the USA (3). Pycnogenol has strong anti-
oxidant and anti-inflammatory activities (4).
The historical development of Pycnogenol and the utiliza-
tion of the pine bark as a health promoting botanical (5) and 
its role in cardiovascular health and blood glucose control has 
been described earlier (6). The concept of orally administered 
Pycnogenol, either as “stand alone product” or in combina-
tion with other food ingredients was developed during last 
two decades. Numerous clinical trials have investigated the 
efficacy of oral Pycnogenol in individuals with CVI (7-14), 
clinical research data being reviewed (6,15-17). 
 
PATHOPHYSIOGY OF CHRONIC VENOUS INSUFFICIENCY
Chronic venous insufficiency is characterized by valvular 
incompetence of the perforator veins, venous stasis, resulting 
in venous hypertension and increase in venular permeability 
leading to edema of the legs and feet (18-20). The six most 
important manifestations involved in CVI are (i) venous stasis 
and hemodynamic alterations, (ii) endothelial dysfunction, (iii) 
edema formation, (iv) collagen destabilization, (v) microcircu-
latory dysfunction, and (vi) leukocyte-endothelial interactions.
Venous stasis and hemodynamic alterations 
During venous stasis, vasomotion frequency in CVI patients 
decreased significantly from 7.4 ± 2.2 cpm to 5.4 ± 2.5 cpm, 
whereas vasomotion frequency in control participants in-
creased significantly from 4.5 ± 1.6 cpm to 8.8 ± 2.5 cpm. The 
failure to increase vasomotion frequency in CVI is considered 
to reflect longer dilatation of the distal venous vessels per time 
unit and increase in hematocrit (21). Continuous long hours 
sitting or standing prolonged bending of legs, pregnancy, over-
weight or obesity lead to venous stasis, increase in hydrostatic 
pressure in the blood vessels, decrease in venous flow and 
increase interstitial osmotic pressure. These events lead to 
increased infiltration of fluid from intravascular compartment 
to extravascular compartment leading to augmentation of legs 
and feet edema. Oxidative stress plays a great role in venous 
stasis and CVI. A statistically significant increase of venous 
pressure of the lower limbs was observed in workers with 
standing occupation (surgery room nurses) associated with 
significantly higher mean levels of reactive oxygen species 
(ROS) (22). These phenomena have also been demonstrated 
in experimental CVI in rats (23) Fluorescence angiography 
technique was used to evaluate the haemodynamic changes and 
these were further confirmed using radioactive microspheres 
technique (23,24). 
Endothelial dysfunction, edema,  
and microcirculatory dysfunction 
Edema of feet and legs is one the most frequent signs of CVI. 
Damage of endothelium is particularly the first relevant event 
in its pathogenesis. Altered vascular permeability and endothe-
lial dysfunction also lead to thrombosis, the well recognized 
and most frequent sign of CVI. These phenomena have earlier 
been demonstrated by simulating an experimental models of 
CVI and of dextran and D-galactosamine-induced edema in 
rats (23-25). The extent of edema depends on the degree of 
damage caused to the endothelium, the extent of accumulation 
of leukocytes, and the degranulation of mast cells releasing his-
tamine (26-28), accompanied by collagen destabilization (29).
Chronic venous insufficiency is associated not only with 
functional and morphologic changes of the deep veins but 
also the microcirculation. In CVI, changes in skin capillaries 
are stage dependent. There is a decrease of capillary density 
from 27 capillaries per cm2 down to 5 capillaries per cm2 in 
CVI stage III as classified by Widmer (30). Edema is resulting 
from capillary leakage as shown by perfusion experiments with 
fluorescent dyes (31). The transcutaneous partial pressure of 
oxygen (TcPO2) is about 57 mm Hg in healthy individuals, 
and decreased stage-dependent in CVI is less than 30 mm Hg 
in stage III Widmer classification. A lack of oxygen is unlikely 
to be primary reason for the development of skin ulcers in CVI 
(32). Impairment of the cutaneous microcirculation is a major 
risk factor in inflammation and ulceration in patients with CVI. 
Increase of capillary filtration rate predisposes to the forma-
tion of edema (33).  Further leukocyte-endothelial interactions 
and ongoing inflammation can be found in CVI, including the 
expression of leukocyte adhesion molecules (34); these might 
be new targets for pharmacologic intervention in CVI (35)
BIOLOGICAL PROFILE OF PYCNOGENOL
Antioxidant and anti-inflammatory activities
Antioxidant and anti-inflammatory profile of Pycnogenol has 
been reviewed (36-39); these biological activities are shown 
in vitro and in vivo models and then have been confirmed  in 
clinical studies. These include: (i) antioxidant and free radical 
scavenging activity (40-44), (ii) antioxidant activity sparing 
vitamin C and recycling of vitamin E (45), (iii) inhibition of 
lipid peroxidation (46), (iv) protection of nerve cells against 
β-amyloid- or glutamate-induced toxicity (47), (v) erythrocytes 
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protection in G6PD deficient human (48), (vi) inhibition of 
generation of inflammatory and oxidative mediators (49-55), 
(vii) inhibition of matrix metalloprotease activity (56), (viii) 
inhibition of histamine release from mast cells (57), and (ix) 
wound healing effects (58,59).  
Antioxidant profile: In vitro studies
Several studies made with Pycnogenol have been reported 
to demonstrate its free radical scavenging and/or antioxidant 
activity in vitro. Free radical (hydroxyl and superoxide) 
scavenging activity was measured using a highly sensitive 
electron spin resonance spectrometer and was compared to 
other bioactive free radical scavengers like ginkgo biloba and 
green tea extract. An analogue of vitamin C and vitamin E were 
used as reference standards for hydroxyl radicals. Superoxide 
dismutase (SOD) was used as the reference standard for super-
oxide anion scavenging activity. Macrophages were activated 
by the bacterial wall components and lipopolysaccharides 
(LPS) and interferon- γ (IFN-γ), which induces the expression 
of large amounts of the enzyme nitric oxide synthase (iNOS). 
Pycnogenol was found to a potent free radical scavenger of 
hydroxyl, superoxide and NO radicals (40,41). Pycnogenol 
participates in the cellular antioxidant network as indicated 
by its ability to regenerate the ascorbyl radical and to protect 
endogenous vitamin E and glutathione from oxidative stress. 
In addition, it was found to be resistant to the action of heat 
and ascorbate oxidase (45). Pycnogenol protects DNA against 
Fenton reaction radicals, probably by chelating Fe. It also can 
induce SOD under oxidative stress (46). In human umbilical 
vein endothelial cell cultures, Pycnogenol exhibited a dose-
dependent suppression of tumor necrosis factor-alpha (TNF-
α)-induced activation of the transcriptional regulatory protein 
nuclear factor-kappa B (NF-κB). Expression of cell surface 
molecules such as VCAM-1 and ICAM-1 was reduced  (47).
In two different in vitro studies, bovine vascular endothelial 
cells were treated with Pycnogenol before subjecting them to 
oxidative stress induced by t-butyl hydroperoxide (t-HBP), 
malondialdehyde (MDA) being used as a biological marker 
to assess lipid peroxidation. Preincubation of endothelial 
cells with Pycnogenol at concentrations 10-80 µg/ml for 16 
h increased the cell viability after t-BHP treatment and, in 
addition, caused a dose-dependent decline in MDA (45,46) . 
In another independent in vitro study model, bovine retina 
as the tissue substrate and lipid peroxidation as the target reac-
tion action giving rise to lipid hydroperoxide as the biological 
marker expressed as thiobarbituric acid reactive substances 
(TBARS), Pycnogenol effectively inhibited lipid peroxidation 
at a concentration as low as 25 ng/ml. Lipid peroxidation was 
inhibited by Pycnogenol in a dose-dependent fashion and was 
completely absent at a concentration of 250 ng/ml. Pycnogenol 
was relatively more effective than grape seed extract, vitamin 
C, vitamin E, and lipolic acid (44).
Antioxidant activity of Pycnogenol was further confirmed by 
using three different in vitro models addressing the oxidative 
burst, LDL oxidation and iron/ascorbic acid system as oxidant 
challenges on different substrates. Pycnogenol exhibited a 
concentration-dependent inhibition of oxidative burst triggered 
by zymosan in J774 murine macrophages in vitro. Pycnogenol 
when coincubated with copper sulphate used to oxidise hu-
man plasma LDL (formation of thiobarbituric acid reactive 
substances, TBARS used as markers) resulted in inhibition 
of LDL oxidation in a concentration dependent manner. Pyc-
nogenol significantly minimised the cleavage of DNA caused 
by hydroxyl radical induced by exposure of pBR322 plasmid 
DNA to iron/ascorbic acid system and measured by agarose 
gel electrophoresis (43). 
Pretreatment of LPS stimulated murine macrophages (RAW 
264.7) associated with increased release of the proinflamatory 
mediators interleukin-1 β (IL-1β) and TNF-α. Incubation with 
Pycnogenol was associated with a dose-dependent decrease 
in these mediators' levels, which blocks  the activation of two 
major "proinflammatory" transcription factors, NF-κB and 
AP-1 (47). 
Antioxidant and anti-inflammatory profile: In vivo 
animal studies
Pycnogenol was shown to have remarkable free radical 
scavenging activity in vitro and anti-inflammatory activity 
in vivo. These activities bear close correlation indicating the 
involvement of free radicals in inflammation and the anti-
inflammatory action of Pycnogenol at least partly due to its free 
radical scavenging effect (40). Anti-inflammatory and wound 
healing effects were demonstrated subsequently by the same 
group of authors (53,54,58).  
There is enough experimental evidence that oxidative 
stress is involved in the pathophysiology of diabetes and its 
complications. In streptozotocin-induced diabetic rats the 
glutathione to glutathione disulfide ratio and the activities 
of endogenous antioxidant enzymes superoxide dismutase, 
catalase, glutathione peroxidase, glutathione reductase, and 
γ glutamyl-transpeptidase were significantly increased after 
Pycnogenol administration. These changes were associated 
with a significant decrease in blood glucose levels in diabetic 
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rats (60). Another study from the same laboratory further 
showed that Pycnogenol administered alone or in combination 
with β carotene, once again increased glutathione reductase 
activities  (61). 
The experiments were repeated focusing on diabetic retinop-
athy in streptozotocin-induced diabetic rats. Decreased retinal 
γ-glutamyl transferase activity of diabetic rats was normalized 
by administration of Pycnogenol alone or in combination with 
β-carotene. Elevated activity of SOD in diabetic retina was 
normalized by Pycnogenol and β-carotene combination (62). 
Clinical research 
The results of the clinical studies showed the efficacy of 
Pycnogenol in patients with CVI and other venocapillary dis-
eases confirming that oxidative stress is important in venous 
diseases and that an antioxidant dietary supplementation with 
Pycnogenol may influence the positive outcome of the CVI. 
The results are consistent with the proposed mechanism of ac-
tion of Pycnogenol: venous blood flow is not modified, while 
a reduced capillary permeability is observed. The reduction 
of the subcutaneous edema and, consequently, of the subjec-
tive feeling of heavy legs might be the result of free radical 
scavenging activity of Pycnogenol. 
Clinical research data on Pycnogenol are provided based on 
its antioxidant activity in healthy volunteers. The effect of Pyc-
nogenol on human antioxidant defenses was  demonstrated by 
a significant (p< 0.05) decrease of oxygen radical absorbance 
capacity in plasma throughout  the Pycnogenol supplementa-
tion period of  three weeks. In addition to its ability to enhance 
plasma antioxidant capacity, Pycnogenol significantly reduced 
LDL-cholesterol levels and increased HDL-cholesterol levels 
in the blood (63). In another independent double-blind study, 
Pycnogenol significantly increased plasma antioxidant activity 
(p <0.01). The level of total cholesterol decreased from 5.41 
to4.98 mmol/L associated with a decrease LDL-cholesterol 
from 3.33 to 2.78 mmol/L(64). 
After oral application of Pycnogenol, two major metabolites 
are formed in vivo, delta-(3,4-dihydroxyphenyl)-gamma-
valerolactone (M1) and delta-(3-methoxy-4-hydroxyphenyl)-
gamma-valerolactone (M2). Both metabolites exert strong 
inhibitory effects on matrix metalloproteinases types 1, 2 and 
9. M1 is also reported to have superoxide scavenger activi-
ties (56).
An acute exposure to ultraviolet radiation (UVR) leads to 
inflammatory response, skin erythema. Oxidative stress by 
releasing ROS and reactive nitrogen species (RNS) is involved 
in producing this biological effect. UVR stimulates expression 
of the proinflammatory genes for TNF-α, IL-1α, IL-1β, IL-6, 
and IL-8. All these cytokines/chemokines contain NF-κB 
binding sites in the 5’flanking region of the gene. 
Pycnogenol produced a significant increase in the dose of 
UVR necessary to achieve standardized erythema response 
(minimum erythema dose) of human skin. The activation 
of NF-κB plays a major role in the UVR-induced erythema. 
Pycnogenol inhibited UVR-induced NF-κB-dependent gene 
expression in a concentration dependent manner (51). 
Oxidative stress is also involved in pathogenesis of other 
clinical conditions like skin ageing, erythema, abnormal sperm 
morphology, and gingival bleeding and plaque formation. The 
effects of Pycnogenol were studied independently in these 
conditions. Supplementation with Pycnogenol along with other 
micronutrients in a formulation Evelle improved visible signs 
of skin aging, increased skin elasticity and decreased skin 
roughness (65). Pycnogenol supplementation provided relief 
from erythema and melasma (51,66). Additionally, Pycnogenol 
by virtue of its antioxidant profile has improved abnormal 
sperm morphology and functions (67), provided relief from 
pain in dysmenorrhea  (68) and minimized gingival bleeding 
and plaque formation (69).
    Fifteen clinical studies have been performed between 1989 
and 1999 in 784 patients suffering from CVI and other venous 
diseases (reviewed in 15). The results of the clinical studies 
show the efficacy of Pycnogenol in patients with CVI and other 
veno-capillary diseases. They confirm that oxidative stress 
plays an important role in venous diseases and the antioxidant 
dietary supplement Pycnogenol may influence the healthy 
outcome of CVI. The results are consistent with the proposed 
mechanism of action of Pycnogenol: venous blood flow is not 
modified, while a reduced capillary permeability is observed: 
the reduction of edema and consequently, of subjective feeling 
of heavy legs might be the result of free radical scavenging 
activity of Pycnogenol and reduced leukocytes adhesion and 
migration in the extravascular spaces. The sealing effect on 
capillaries results from strong tissue binding of Pycnogenol 
leading to a cross linking of proteins of the vessel wall, which 
may contribute to reduction in edema formation.
Anti-edema effect in chronic venous insufficiency
A double-blind placebo-controlled clinical study was per-
formed to investigate the efficacy of Pycnogenol in CVI. Forty 
patients with CVI and varices of the legs were randomly as-
signed to a treatment with Pycnogenol, 100 mg x 3/day or a 
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placebo for 2 months. The effects were evaluated by scoring 
the symptomatology with a semi-quantitative scale, and the 
venous blood flow by means of a hand-held Doppler ultrasound 
(venous blood flow meter). Pycnogenol supplementation pro-
duced a significant reduction in subcutaneous edema as well as 
heaviness and pain in the legs, on both after 30 and 60 days, 
the evaluation time periods. Approximately 60% of patients 
treated with Pycnogenol experienced a complete disappearance 
of edema (the most rapidly disappearing symptom) and pain 
at the end of supplementation, while almost all the patients 
reported a reduction in leg heaviness which disappeared in 
approximately 33% of patients. These changes were statisti-
cally significant. No effect was observed in the placebo-treated 
subjects. No effect on the venous blood flow was observed in 
either of the experimental groups (7). The results were con-
firmed in a subsequent clinical study. This study was performed 
in two phases. First phase consisted of a double-blind phase 
– in which 20 patients were recruited and randomly treated 
with placebo or Pycnogenol (100 mg 3/day for 2 months), and 
second phase represented an open phase – in which other 20 
patients were supplemented with Pycnogenol at the same dose 
schedule. In total, 40 patients were enrolled; 30 of them were 
treated with Pycnogenol and 10 with placebo. Pycnogenol 
significantly improved the legs’ heaviness and subcutaneous 
edema; the venous pressure was also significantly reduced by 
this nutraceutical. Clinically, capillary leakage, perivascular 
inflammation and subcutaneous edema were all reduced (8). 
The above two studies were followed by a comparative 
clinical study, where efficacy of food supplement Pycnogenol 
was compared to standard drug Venostasin (horse chestnut 
seed extract) in CVI. 40 patients with diagnosed CVI were 
administered either 600 mg Venostasin or 360 mg Pycnogenol 
per day over a period of 4 weeks. The following parameters 
were investigated before the start and after 2 and 4 weeks 
of treatment: circumference of the lower legs and rating of 
subjective symptoms (scores) of pain, cramps, night-time 
swelling, feeling of “heaviness”, and reddening of the skin. 
In addition, blood levels of cholesterol LDL and HDL were 
determined before and at the end of treatment. Pycnogenol 
significantly reduced the circumference of the lower limbs and 
significantly improved subjective symptoms. Furthermore, it 
significantly decreased LDL-cholesterol values in the blood, 
whereas HDL-cholesterol remained unaffected. Venostasin 
only moderately but not significantly, reduced the circumfer-
ence of the lower limbs and marginally improved symptoms. 
Venostasin had no influence on the determined lipid values. 
In conclusion, Pycnogenol was found to be more efficacious 
than Venostasin (9).
In a study with 18 patients suffering from venous malleolar 
ulcers, Pycnogenol was applied orally or orally and topically 
for 6 weeks. Ulcer healing was faster in the combination 
group, but both treatment groups showed a reduction of the 
permalleolar edema. This was interpreted as an improvement 
of local microcirculation (59).
Effects on venous tone 
A placebo-controlled double-blind study with Pycnogenol (360 
mg/day for 5 days) in 40 patients suffering from venous cir-
culation problems is reported. Its efficacy has been confirmed 
on the basis of objective and subjective signs and symptoms 
of static edema. The continuous sitting for 2 hours was used 
to induce stasis edema. Objective evaluation parameter was 
swelling of leg: lower leg volume was measured using the 
method of Artzler and Herbst with modified apparatus (water 
displacement technique. Subjective evaluation parameters 
were signs and symptoms, using 5-point scores. These were 
heaviness, pain, itching and night cramp. The comparative 
volume measurement after 2 hours sitting position revealed 
impressive differences between Pycnogenol treated group and 
placebo group. Whereas the resting volume was somewhat 
higher in the placebo group patients at the end of treatment, 
these values significantly decrease in Pycnogenol treated group 
(p < 0.01). In a placebo-controlled double blind study in 29 
patients, it was possible to detect a significant reduction (p < 
0.01) of venous stasis (sitting for 1 and 2 hours respectively) 
oedema after 4 days treatment with Pycnogenol at a dose 180 
mg/day in comparison to placebo (11).
Anti-edema effect in healthy subjects during long 
flights
The anti-edema effects of Pycnogenol was evaluated during 
long-haul flights in asymptomatic subjects. The assessment 
of edema was performed by evaluating an analogue scale, the 
rate of ankle swelling by strain-gauge derived rate of ankle 
swelling (RAS), and by assessing the ankle circumference 
variation. The study included 211 subjects; 169 completed 
the study (88 in the control group and 81 in the Pycnogenol 
group). There were no important differences between the two 
groups (comparable for age, gender, weight, body mass index, 
and pattern distribution). The oedema score, the RAS, and the 
circumference at inclusion were also comparable. After the 
flight, in subjects treated with Pycnogenol the oedema score 
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was increased only by 17.9% (vs. an increase of 58.3% in the 
control group) (p<0.05). The RAS, evaluated in 22 subjects in 
the Pycnogenol group (age 44.5; SD 8) and in 23 in the control 
group (age 45; SD 9) was increased on average by 91% in the 
control group and 36% in the Pycnogenol group (p<0.05). 
The variation on circumference at the ankle was 6% in the 
Pycnogenol group (11% in the control group; p<0.05). These 
results indicate a positive effect of Pycnogenol on oedema 
during long flights when considering subjective and objective 
data. No unwanted effects were observed (70,71).
Microcirculatory function 
A clinical study was performed to investigate the clinical 
efficacy of oral Pycnogenol in patients with severe CVI in 
comparison was the combination of diosmin and hesperidin 
Daflon. A group of 86 patients with severe CVI, venous hy-
pertension, ankle swelling and previous history of venous 
ulcerations received either oral Pycnogenol (capsules) 150 
mg or 300 mg daily for 8 weeks or Daflon, 1,000 mg/day. At 
the end of the study, microcirculatory results indicated: (i) a 
progressive decrease of skin flux at rest (RF), (ii) a significant 
decrease in capillary filtration, (iii) an improvement in the 
symptomatic venous score, (iv) edema reduction, and (v) a 
significant improvement (increase) in pO2 and a decrease in 
pCO2 in the Pycnogenol group. 
A significant level of improvement was reached after 4 weeks 
of treatment in most patients (p < .05) of the Pycnogenol group 
while clinical improvement was significant only in 6 subjects 
in the Daflon group. The positive effects of treatment with 
Pycnogenol after 8 weeks were significantly more important 
in comparison with the Daflon group. In conclusion, this study 
confirms the fast clinical efficacy of Pycnogenol in patients 
with chronic venous insufficiency and venous microangiopathy 
and its superiority – considering the evaluated parameters – to 
the combination of diosmin and hesperidin (13). 
Microscopic evaluation of microvessels at the root of the 
finger’s nails showed that consumption of 60 mg Pycnogenol 
per day for 4 weeks significantly dilate these vessels and im-
prove microcirculation. After discontinuation of Pycnogenol 
the improved microcirculation persists for up to 4 weeks. When 
Pycnogenol tablets were chewed an increased microcirculatory 
blood flow was observed in 78% of the subjects   (72). 
Improvement in cramps and muscular pain 
A clinical study was performed to assess the action of Pyc-
nogenol on cramps and muscular pain in different groups of 
subjects including patients with CVI. Cramps in legs are very 
common in CVI. The study included a 5-week observation 
period (4 weeks treatment and one follow-up week after the 
suspension of treatment) to evaluate the efficacy of Pycnogenol 
after its withdrawal. Four 50 mg capsules (total dose 200 mg/
day) were prescribed with suggestion to drink at least 1.5 lit-
ers of water every day. In the first part of the study 66 healthy 
subjects completed a 5-week follow-up period. The difference 
between number of cramps attacks recorded within the 2 weeks 
before inclusion and the number of episodes during the fourth 
(p <0.05) and fifth (p <0.05) week were statistically signifi-
cant. In normal subjects the average number of episodes was 
reduced from 4.8 (1.2) events per week to 1.3 (1.1) at 4 weeks 
(p <0.05). In venous patients the decrease in events was from 
6.3 (1.1) to 2.6 (0.4) per week (p <0.05). In athletes the number 
of episodes decreased from 8.6 (2) to 2.4 (0.5) (p <0.05). The 
decrease was still present at 5 weeks in the 3 groups, to levels 
significantly lower than inclusion values (p <0.05). There was 
a significant decrease in the number of cramps episodes (p 
<0.05) and in the score concerning muscular pain (p < 0.05) in 
claudicants and diabetics. No significant effects were observed 
in the placebo groups. Altogether, these results suggest that 
the use of Pycnogenol prevents cramps, muscular pain at rest, 
and pain after/during exercise in normal, in athletes prone to 
cramps, and in patients with venous disease (14). 
 
Antithrombotic effect in healthy subjects during long 
flights 
A clinical study was performed to evaluate the occurrence of 
deep venous thrombosis (DVT) and superficial vein throm-
bosis (SVT) and its prophylaxis with Pycnogenol, in long-
haul flights, in subjects at moderate to high-risk of DVT and 
SVT. The study pre-included 244 pre-selected subjects; 211 
were included (33 were excluded for several reasons due to 
logistic problems) and 198 completed the study; 13 subjects 
were lost for follow-up at the end of the flight, all for non-
medical problems (i.e., for difficult connections). All subjects 
were scanned within 90 minutes before the flight and within 
2 hours after disembarking. Subjects were supplemented with 
100 mg Pycnogenol per capsule. Treatment subjects received 
two capsules between 2 and 3 hours before flights with 250 
mL of water; two capsules were taken 6 hours later with 250 
mL of water and one capsule the next day. The control group 
received comparable placebo at the same intervals. The flight 
duration was on average 8 hours and 15 minutes (SD 55 min) 
(range 7.45-12.33). In the control group there were five throm-
botic events (one DVT and four superficial thromboses) while 
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only non thrombotic, localized phlebitis was observed in the 
Pycnogenol group (5.15% vs. no events; p<0.025). The ITT 
(intention to treat) analysis detects 13 failures in the control 
group (eight lost to follow up + five thrombotic events) of 105 
subjects (12.4%) vs. five failures (4.7%; all lost, no thrombotic 
events) in the treatment group (p<0.025). No unwanted effects 
were observed. In conclusion, this study indicates that Pyc-
nogenol treatment was effective in decreasing the number of 
thrombotic events (DVT and SVT) in moderate-to-high risk 
subjects, during long-haul flights. 
Based on antithrombotic effect of Pycnogenol, a rationale 
to develop a concept of another combination product with 
Pycnogenol and Ginger extract was developed and realized to 
give rise to a new formulation Zinopin (73) which was clini-
cally tested in long halt flights for its efficacy on thrombotic 
events and motion sickness (74). 
Healing of venous ulcers
The above findings were applied to a clinical situation in a dou-
ble blind clinical study performed in patients with CVI. Chron-
ic venous insufficiency causes a well-defined microangiopathy 
described as venous hypertensive microangiopathy (VHM) 
leading to venous ulcerations, which is mainly observed in 
the distal part of the leg. In VHM edema is the consequence 
of increased capillary pressure and reduced local clearance, 
and this affects local perfusion. The healing of venous ulcers 
is usually very slow. Oral Pycnogenol is effective in venous 
disease and particularly in controlling edema. The aim of this 
study was the evaluation of the local effects of Pycnogenol on 
ulcers healing associated with venous hypertension. The study 
lasted 6 weeks including 18 patients (16 completed the study) 
with venous ulcerations. The oral treatment with Pycnogenol 
was compared to a combination treatment including oral and 
local treatment. In subjects treated with the combination treat-
ment (oral and local), venous ulcers healed better (there was 
a faster reduction in ulcerated area) in comparison with oral 
treatment only. According to this pilot study Pycnogenol ap-
pears to have an important role in reducing the risk of venous 
ulcers improving their healing (59).
A subsequent double blind clinical study was performed to 
investigate the Clinical efficacy of oral Pycnogenol in patients 
with severe chronic venous insufficiency Patients received oral 
Pycnogenol (50 mg capsules, 3 times daily for a total of 150mg 
daily) for 8 weeks. A group of 21 patients was included in the 
Pycnogenol group and 18 equivalent patients were observed 
as controls. All 21 patients (age 53 years; range, 42-60 years; 
M: F = 11:10) in the Pycnogenol group completed the 8-week 
study period. In all supplemented subjects, microcirculatory 
and clinical evaluations indicated a progressive decrease in 
skin influx, indicating an improvement in the level of micro-
angiopathy: a significant decrease in capillary filtration; a 
significant improvement in the symptomatic score; and a 
reduction in edema. Pycnogenol supplementation may thus 
reduce the risk of ulcerations by controlling the level of venous 
microangiopathy (75) .
Pycnogenol decreases serum thromboxane levels and 
thus inhibits thrombogenesis
In smokers, thromboxane A2 (TxA2) released from platelets 
gets converted to thrombxane B2 (TXB2), a powerful vaso-
constrictor. Smoking induces increased in circulating levels of 
TxB2. In a clinical study performed in smokers, Pycnogenol 
administration at a dose of 200 mg/day lowered TxB2 levels 
to those of non-smokers, whereas showing no effect on the 
already low levels of thromboxane B2 in nonsmokers. In effect, 
Pycnogenol supplementation reduces a risk factor for venous 
thrombosis (76). These findings were confirmed in another 
independent double-blind, randomized, cross-over study in 
11 human subjects with high blood pressure it was shown that 
Pycnogenol administered at a daily dose of 200 mg for 8 weeks 
significantly (p < 0.05) decreased serum TxB2 in serum from 
baseline 151 ± 4 ng/mL to 134 ± 5 ng/mL (77).
Pycnogenol improves blood flow through nitric 
oxide-mediated vasorelaxation
A central role of Pycnogenol is its ability to enhance en-
dothelial production of NO from the substrate L-arginine, 
by the enzyme NOS. In an in vitro study it was shown that 
Pycnogenol, in a dose concentration range of 1-10 µg/ml re-
laxed epinephrine-, norepinephrine- or phenylephrine-induced 
contraction of the rat aorta. However, when the endothelial 
lining of the aortic ring was removed, Pycnogenol produced 
no effect, indicating an endothelium dependent relaxing (EDR) 
effect. This response was caused by enhanced NO levels, 
because the NOS inhibitor N-methyl-L arginine (NMA) re-
versed the relaxation, and this response in turn was reversed 
by addition of L-arginine. Pycnogenol-induced EDR persisted 
after exposure of intact rings to high levels of SOD, suggest-
ing that the mechanism of EDR did not involve scavenging 
of superoxide anion (78). In addition to causing relaxation, 
preincubation of aortic rings with Pycnogenol (1-10 µg/ml) 
inhibited subsequent E- and NE-induced aortic contractions 
in a concentration dependent manner. Three fractions of the 
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extract were used. It was interesting to note that fraction thee 
with oligomeric procyanidins exhibited potent EDR activity. 
It was concluded that Pycnogenol in addition to its known 
antioxidant activity stimulates constitutive endothelial NOS 
(eNOS) activity and increases the NO levels, which could 
counteract the vasoconstrictions induced by epinephrine and 
norepinephrine. Furthermore, additional protective effects 
could result from the well-known established properties of NO 
to decrease platelet aggregation and adhesions (79), as well 
as to inhibit LDL cholesterol oxidation (80). All these could 
protect against atherogenesis and thrombus formation, known 
risk factors in CV (78). These findings led to the proposition 
that Pycnogenol stimulates production of NO from L-arginine 
by eNOS  (16). It remains to be tested whether Pycnogenol 
may influence the release of vasoactive substances from 
perivascular adipose tissue (see 81).
Pycnogenol normalizes blood platelet activity
The activation of platelets represents an important contributory 
factor in the pathogenesis of thrombosis (82). The effects of 
Pycnogenol supplementation were assessed on platelet func-
tion of cigarette smokers. In this population, a two fold increase 
of adrenaline levels and enhanced platelet activity is observed. 
Smoking is a well defined cardiovascular disease risk factor 
as already stated above. The increased platelet reactivity and 
aggregation observed 2 hours after smoking were inhibited by a 
single dose of either 500 mg of acetyl salicylic acid or 100 mg 
of Pycnogenol. This inhibitory effect on platelet reactivity/ag-
gregation followed a clear dose response relationship, starting 
from a dose of 25 mg to complete absence of platelet aggrega-
tion observed 200 mg of Pycnogenol, the effect persisting for 
6 days (83). Likewise, heavy smokers were given Pycnogenol 
at a daily dose of 200 mg for 8 weeks. The platelet aggregation 
index was significantly reduced at the end of the experiment; 
a comparison with a normal non-smoker population showed 
that the platelet reactivity was almost reduced to the normal 
values of a control healthy population. Pycnogenol adminis-
tration lowered the level of TxB2, a powerful vasoconstrictor 
and platelet aggregating agent (84). 
CONCLUSION
Pycnogenol protects vascular endothelium, decreases capillary 
fragility, increase capillary resistance thus reduces vascular 
permeability, contributing to reduction of edema. It prevents 
thrombus formation through inhibiting platelet aggregation, 
improves microcirculatory function. It protects collagen 
degradation and increases its regeneration and produces capil-
lary sealing effect through its specific binding capacity with 
collagen. All these activities of Pycnogenol contribute to its 
beneficial effects in CVI as a food supplement. 
Developing new combination products using synergistic ap-
proaches are the future trends of research and development to 
prove efficacy in conditions which involves oxidative stress, 
inflammation, endothelial dysfunction, thrombogenesis, and 
ulceration.
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